Sanofi will work with the Biomedical Advanced Research and Development Authority to retrofit vaccine manufacturing facilities in Swiftwater, Pa. The effort will double Sanofi’s capacity to manufacture a recombinant protein-based flu shot.
The agreement gives HHS access to the drugmaker’s vaccine production capacity for up to 25 years, which translates into nearly 1 million flu shot doses for use during a pandemic.
Sanofi is the only drugmaker licensed to manufacture a recombinant flu shot in the U.S., which is much quicker to produce than traditional egg-based vaccines.
More articles on clinical leadership & infection control:
Mount Sinai’s ED is a ‘war zone,’ nurse says
Dallas children’s hospital relocates 28 patients after mold discovery
Police raid Georgia psych hospital over abuse allegations
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
